Literature DB >> 29935044

Tau uptake in agrammatic primary progressive aphasia with and without apraxia of speech.

R L Utianski1, J L Whitwell2, C G Schwarz2, J R Duffy1, H Botha1, H M Clark1, M M Machulda3, M L Senjem2,4, D S Knopman1, R C Petersen1, C R Jack2, V J Lowe2, K A Josephs1.   

Abstract

BACKGROUND AND
PURPOSE: The non-fluent/agrammatic variant of primary progressive aphasia (agPPA) is a heterogeneous diagnosis wherein some individuals have apraxia of speech (AOS). When agPPA includes AOS, a tauopathy is the likely underlying pathology. Recently, [18F]AV-1451 was developed for the in-vivo assessment of tau. In this study, we compared patterns of tau tracer uptake in patients with agPPA with and without AOS.
METHODS: Nine patients with agPPA (four without AOS) underwent tau positron emission tomography imaging with [18F]AV-1451. Uptake of [18F]AV-1451 was assessed as cortical to cerebellar crus ratio (standard uptake value ratio) in cortical regions of interest measured using the MCALT atlas and compared voxel-wise in SPM12. Each patient was age- and sex-matched to three controls.
RESULTS: The agPPA without AOS showed uptake in the left frontal and temporal lobes, whereas agPPA with AOS showed uptake in the bilateral supplementary motor areas, frontal lobes, precuneus and precentral gyrus relative to controls. The left precentral gyrus had uptake in agPPA with AOS relative to those without AOS.
CONCLUSIONS: This cross-sectional study suggests that [18F]AV-1451 uptake in the precentral gyrus is implicated in AOS in agPPA.
© 2018 EAN.

Entities:  

Keywords:  [18F]AV-1451; apraxia of speech; primary progressive aphasia; tau positron emission tomography

Mesh:

Substances:

Year:  2018        PMID: 29935044      PMCID: PMC6181763          DOI: 10.1111/ene.13733

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  20 in total

1.  Classification of primary progressive aphasia and its variants.

Authors:  M L Gorno-Tempini; A E Hillis; S Weintraub; A Kertesz; M Mendez; S F Cappa; J M Ogar; J D Rohrer; S Black; B F Boeve; F Manes; N F Dronkers; R Vandenberghe; K Rascovsky; K Patterson; B L Miller; D S Knopman; J R Hodges; M M Mesulam; M Grossman
Journal:  Neurology       Date:  2011-02-16       Impact factor: 9.910

2.  [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration.

Authors:  Keith A Josephs; Jennifer L Whitwell; Pawel Tacik; Joseph R Duffy; Matthew L Senjem; Nirubol Tosakulwong; Clifford R Jack; Val Lowe; Dennis W Dickson; Melissa E Murray
Journal:  Acta Neuropathol       Date:  2016-09-19       Impact factor: 17.088

3.  Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech.

Authors:  Rene L Utianski; Jennifer L Whitwell; Christopher G Schwarz; Matthew L Senjem; Nirubol Tosakulwong; Joseph R Duffy; Heather M Clark; Mary M Machulda; Ronald C Petersen; Clifford R Jack; Val J Lowe; Keith A Josephs
Journal:  Cortex       Date:  2018-01-02       Impact factor: 4.027

4.  Prediction of pathology in primary progressive language and speech disorders.

Authors:  V Deramecourt; F Lebert; B Debachy; M A Mackowiak-Cordoliani; S Bombois; O Kerdraon; L Buée; C-A Maurage; F Pasquier
Journal:  Neurology       Date:  2009-11-25       Impact factor: 9.910

5.  Slowly progressive aphasia without generalized dementia.

Authors:  M M Mesulam
Journal:  Ann Neurol       Date:  1982-06       Impact factor: 10.422

6.  Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech.

Authors:  Hugo Botha; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Neurology       Date:  2014-04-11       Impact factor: 9.910

7.  Classification and pathology of primary progressive aphasia.

Authors:  Jennifer M Harris; Claire Gall; Jennifer C Thompson; Anna M T Richardson; David Neary; Daniel du Plessis; Piyali Pal; David M A Mann; Julie S Snowden; Matthew Jones
Journal:  Neurology       Date:  2013-10-18       Impact factor: 9.910

8.  Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech.

Authors:  Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Ankit V Master; Val J Lowe; Clifford R Jack; Jennifer L Whitwell
Journal:  Brain       Date:  2012-03-01       Impact factor: 13.501

9.  Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases.

Authors:  Stephen N Gomperts; Joseph J Locascio; Sara J Makaretz; Aaron Schultz; Christina Caso; Neil Vasdev; Reisa Sperling; John H Growdon; Bradford C Dickerson; Keith Johnson
Journal:  JAMA Neurol       Date:  2016-11-01       Impact factor: 18.302

10.  An autoradiographic evaluation of AV-1451 Tau PET in dementia.

Authors:  Val J Lowe; Geoffry Curran; Ping Fang; Amanda M Liesinger; Keith A Josephs; Joseph E Parisi; Kejal Kantarci; Bradley F Boeve; Mukesh K Pandey; Tyler Bruinsma; David S Knopman; David T Jones; Leonard Petrucelli; Casey N Cook; Neill R Graff-Radford; Dennis W Dickson; Ronald C Petersen; Clifford R Jack; Melissa E Murray
Journal:  Acta Neuropathol Commun       Date:  2016-06-13       Impact factor: 7.801

View more
  10 in total

Review 1.  FTD spectrum: Neuroimaging across the FTD spectrum.

Authors:  Jennifer L Whitwell
Journal:  Prog Mol Biol Transl Sci       Date:  2019-06-18       Impact factor: 3.622

2.  Prominent auditory deficits in primary progressive aphasia: A case study.

Authors:  Rene L Utianski; Joseph R Duffy; Heather M Clark; Mary M Machulda; Dennis W Dickson; Jennifer L Whitwell; Keith A Josephs
Journal:  Cortex       Date:  2019-02-21       Impact factor: 4.027

3.  Longitudinal flortaucipir ([18F]AV-1451) PET imaging in primary progressive apraxia of speech.

Authors:  Rene L Utianski; Peter R Martin; Hugo Botha; Christopher G Schwarz; Joseph R Duffy; Ronald C Petersen; David S Knopman; Heather M Clark; Alissa M Butts; Mary M Machulda; Clifford R Jack; Val J Lowe; Jennifer L Whitwell; Keith A Josephs
Journal:  Cortex       Date:  2019-11-19       Impact factor: 4.027

4.  Electroencephalography in Primary Progressive Aphasia and Apraxia of Speech.

Authors:  Rene L Utianski; John N Caviness; Gregory A Worrell; Joseph R Duffy; Heather M Clark; Mary M Machulda; Jennifer L Whitwell; Keith A Josephs
Journal:  Aphasiology       Date:  2018-11-16       Impact factor: 2.773

5.  Primary Progressive Apraxia of Speech: From Recognition to Diagnosis and Care.

Authors:  Joseph R Duffy; Rene L Utianski; Keith A Josephs
Journal:  Aphasiology       Date:  2020-07-07       Impact factor: 2.773

6.  Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Hugo Botha; Farwa Ali; Heather M Clark; Joseph R Duffy; Rene L Utianski; Chase A Stevens; Stephen D Weigand; Christopher G Schwarz; Matthew L Senjem; Clifford R Jack; Val J Lowe; J Eric Ahlskog; Dennis W Dickson; Keith A Josephs
Journal:  Neuroimage Clin       Date:  2019-12-28       Impact factor: 4.881

Review 7.  Differential Diagnosis of Apraxia of Speech in Children and Adults: A Scoping Review.

Authors:  Kristen M Allison; Claire Cordella; Jenya Iuzzini-Seigel; Jordan R Green
Journal:  J Speech Lang Hear Res       Date:  2020-08-12       Impact factor: 2.297

8.  Modelling speech motor programming and apraxia of speech in the DIVA/GODIVA neurocomputational framework.

Authors:  Hilary E Miller; Frank H Guenther
Journal:  Aphasiology       Date:  2020-05-18       Impact factor: 2.773

9.  Neuropsychological Profiles of Patients with Progressive Apraxia of Speech and Aphasia.

Authors:  Angelina J Polsinelli; Mary M Machulda; Peter R Martin; Joseph R Duffy; Heather M Clark; Alissa M Butts; Hugo Botha; Val J Lowe; Jennifer L Whitwell; Keith A Josephs; Rene L Utianski
Journal:  J Int Neuropsychol Soc       Date:  2021-07-22       Impact factor: 3.114

Review 10.  Neuroimaging in Frontotemporal Dementia: Heterogeneity and Relationships with Underlying Neuropathology.

Authors:  Bradley T Peet; Salvatore Spina; Nidhi Mundada; Renaud La Joie
Journal:  Neurotherapeutics       Date:  2021-08-13       Impact factor: 7.620

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.